在第二阶段试验中,慢性肾病患者的尿液中的蛋白质大大降低。 A new drug, apecotrep, greatly reduced protein in urine among chronic kidney disease patients in a Phase II trial.

博林格英格尔海姆报告说,其实验药物apecotrep在II期临床试验中显著减少了慢性病患者的蛋白尿,这标志着相关疾病潜在治疗的有前途发展. Boehringer Ingelheim reports that its experimental drug apecotrep significantly reduced proteinuria in patients with chronic kidney disease during a Phase II clinical trial, marking a promising development in potential treatments for kidney-related conditions.